ARCT vs. STOK, PRTC, AUPH, LBPH, IMNM, TNGX, ZNTL, NRIX, IRON, and PRAX
Should you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Stoke Therapeutics (STOK), PureTech Health (PRTC), Aurinia Pharmaceuticals (AUPH), Longboard Pharmaceuticals (LBPH), Immunome (IMNM), Tango Therapeutics (TNGX), Zentalis Pharmaceuticals (ZNTL), Nurix Therapeutics (NRIX), Disc Medicine (IRON), and Praxis Precision Medicines (PRAX). These companies are all part of the "medical" sector.
Arcturus Therapeutics (NASDAQ:ARCT) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends.
Stoke Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -81.59%. Arcturus Therapeutics' return on equity of -37.61% beat Stoke Therapeutics' return on equity.
In the previous week, Arcturus Therapeutics had 4 more articles in the media than Stoke Therapeutics. MarketBeat recorded 12 mentions for Arcturus Therapeutics and 8 mentions for Stoke Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.93 beat Stoke Therapeutics' score of 0.62 indicating that Arcturus Therapeutics is being referred to more favorably in the media.
Arcturus Therapeutics presently has a consensus target price of $64.86, suggesting a potential upside of 68.85%. Stoke Therapeutics has a consensus target price of $20.57, suggesting a potential upside of 46.26%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Arcturus Therapeutics is more favorable than Stoke Therapeutics.
Arcturus Therapeutics has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
Arcturus Therapeutics received 328 more outperform votes than Stoke Therapeutics when rated by MarketBeat users. However, 72.99% of users gave Stoke Therapeutics an outperform vote while only 65.44% of users gave Arcturus Therapeutics an outperform vote.
Arcturus Therapeutics has higher revenue and earnings than Stoke Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
94.5% of Arcturus Therapeutics shares are held by institutional investors. 13.8% of Arcturus Therapeutics shares are held by insiders. Comparatively, 11.3% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Arcturus Therapeutics beats Stoke Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Arcturus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcturus Therapeutics Competitors List
Related Companies and Tools
